You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
Wall Street analysts are bullish on the firm's cell selection platform technology, which could find a total addressable market of more than $20 billion.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.
The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.
The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair.
Canaccord and William Blair also increased their price targets on Quidel's shares, following its acquisition of certain Alere assets and assays.
The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.
The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.
Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.
In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.